<p>Professor of Otolaryngology, ENT Department, Faculty of Medicine, Alexandria University, EGYPT.</p> <p>Senior Consultant Otology, Neurotology, Skull Base Surgery.</p> <p>Past-President and founding member of the International Working Group on Endoscopic Ear Surgery (IWGEES)</p> <p>President of the Egyptian Society of Skull Base Surgery; Egypt (ESSBS)</p> <p>Member of the American Academy of Otolaryngology-Head and Neck Surgery (AAOHNS) - USA.</p> <p>Member of the French Society of Otorhinolaryngology; France.</p> <p>Member of the Association for Research in Otolaryngology (ARO), U.S.A.</p> <p>Member of the Prosper Meniere's Society; Colorado, U.S.A.</p> <p>Professor of Otolaryngology, ENT Department, Faculty of Medicine, Alexandria University, EGYPT.</p> <p>Senior Consultant Otology, Neurotology, Skull Base Surgery.</p> <p>Past-President and founding member of the International Working Group on Endoscopic Ear Surgery (IWGEES)</p> <p>President of the Egyptian Society of Skull Base Surgery; Egypt (ESSBS)</p> <p>Member of the American Academy of Otolaryngology-Head and Neck Surgery (AAOHNS) - USA.</p> <p>Member of the French Society of Otorhinolaryngology; France.</p> <p>Member of the Association for Research in Otolaryngology (ARO), U.S.A.</p> <p>Member of the Prosper Meniere's Society; Colorado, U.S.A</p>

<p>Daniel Lee is the Ansin Foundation Chair in Otolaryngology at the Massachusetts Eye and Ear Infirmary (MEEI) and Harvard Medical School. He is Director of Pediatric Otology and Neurotology, Program Director of the Harvard Neurotology Fellowship and Director of International Patient Services in the Department of Otolaryngology at MEEI. Dr. Lee's funded basic and translational research group seeks to answer fundamental questions about central auditory processing and how to improve auditory brainstem implant outcomes for patients with Neurofibromatosis Type 2 (NF2). He has developed an international center for the care of patients with superior canal dehiscence syndrome, endoscopic ear surgery, and complex cochlear and auditory brainstem implant surgery. He serves on the scientific advisory board for Skylark Bio, a Cambridge, Massachusetts-based company focusing on gene therapy for children with GJB2 related congenital hearing loss.</p>